Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Optimal use of G-CSF administration after hematopoietic SCT

Abstract

After hematopoietic SCT (HSCT), G-CSF is commonly used to enhance stem cell engraftment to minimize the morbidity and mortality associated with prolonged neutropenia. However, there is no consensus on the optimal use of G-CSF after high-dose chemotherapy followed by HSCT. This review was performed to evaluate the evidence regarding the use of G-CSF after autologous and allogeneic HSCT. Studies investigating the use of G-CSF in comparison to control (observation or placebo), early vs delayed initiation of G-CSF, and other approaches driven by patient-specific parameters to identify optimal use of G-CSF have been reviewed. Various outcomes such as neutrophil and platelet engraftment, post-transplant length of hospital stay, post-transplant complications such as infection and GVHD, and survival have been assessed. Finally, we provide the level of evidence for each of the outcomes analyzed while evaluating strategies for using G-CSF in patients undergoing autologous or allogeneic HSCT.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Mossad SB, Longworth DL, Goormastic M, Serkey JM, Keys TF, Bolwell BJ . Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996; 18: 265–271.

    CAS  PubMed  Google Scholar 

  2. Afessa B, Peters SG . Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med 2006; 27: 297–309.

    Article  PubMed  Google Scholar 

  3. Smith LA, Wright-Kanuth MS . Complications and risks in hematopoietic stem cell transplant patients. Clin Lab Sci 2001; 14: 118–124.

    CAS  PubMed  Google Scholar 

  4. Junghanss C, Marr KA . Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture? Curr Opin Infect Dis 2002; 15: 347–353.

    Article  PubMed  Google Scholar 

  5. Richard S, Schuster MW . Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep 2002; 1: 103–109.

    PubMed  Google Scholar 

  6. Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D et al. Stem cell mobilization. Hematology Am Soc Hematol Educ Program 2003, 419–437.

    Article  Google Scholar 

  7. Morris ES, MacDonald KP, Hill GR . Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood 2006; 107: 3430–3435.

    Article  CAS  PubMed  Google Scholar 

  8. Reddy RL . Mobilization and collection of peripheral blood progenitor cells for transplantation. Transfus Apher Sci 2005; 32: 63–72.

    Article  PubMed  Google Scholar 

  9. Anderlini P, Champlin R . Use of filgrastim for stem cell mobilisation and transplantation in high-dose cancer chemotherapy. Drugs 2002; 62 (Suppl 1): 79–88.

    Article  CAS  PubMed  Google Scholar 

  10. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS . Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13: 1323–1327.

    Article  CAS  PubMed  Google Scholar 

  11. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH . Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997; 15: 451–457.

    Article  CAS  PubMed  Google Scholar 

  12. Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96: 80–85.

    CAS  PubMed  Google Scholar 

  13. Ozcan M, Ustun C, Akcaglayan E, Akan H, Arslan O, Ilhan O et al. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 27: 499–505.

    Article  CAS  PubMed  Google Scholar 

  14. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187–3205.

    Article  CAS  PubMed  Google Scholar 

  15. Oxford Centre for Evidence-based Medicine. Levels of evidence. May 2001. Produced by Phillips B, Ball C, Sackett D, et al., since November 1998. Available at: www.cebm.net/index.aspx?o=1047. Accessed January 06, 2008.

  16. Faber E, Pytlik R, Slaby J, Zapletalova J, Kozak T, Raida L et al. Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma—results of a prospective multicentre controlled trial. Eur J Haematol 2006; 77: 493–500.

    Article  CAS  PubMed  Google Scholar 

  17. Schmitz N, Ljungman P, Cordonnier C, Kempf C, Linkesch W, Alegre A et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplant 2004; 34: 955–962.

    Article  CAS  PubMed  Google Scholar 

  18. Brice P, Divine M, Marolleau JP, Haioun C, Dalcortivo L, Sitthy X et al. Comparison of autografting using mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas. Bone Marrow Transplant 1994; 14: 51–55.

    CAS  PubMed  Google Scholar 

  19. Cortelazzo S, Viero P, Bellavita P, Rossi A, Buelli M, Borleri GM et al. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 935–941.

    Article  CAS  PubMed  Google Scholar 

  20. Demirer T, Ayli M, Dagli M, Haznedar R, Genc Y, Fen T et al. Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. Br J Haematol 2002; 118: 1104–1111.

    Article  CAS  PubMed  Google Scholar 

  21. Dunlop DJ, Fitzsimons EJ, McMurray A, Morrison M, Kyle E, Alcorn MJ et al. Filgrastim fails to improve haemopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue. Br J Cancer 1994; 70: 943–945.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Hornedo J, Sola C, Solano C, Lopez JJ, Alonso S, Lluch A et al. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Transplant 2002; 29: 737–743.

    Article  CAS  PubMed  Google Scholar 

  23. Lee SM, Radford JA, Dobson L, Huq T, Ryder WD, Pettengell R et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br J Cancer 1998; 77: 1294–1299.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ojeda E, Garcia-Bustos J, Aguado M, Arrieta R, Quevedo E, Yuste VJ et al. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Bone Marrow Transplant 1999; 24: 601–607.

    Article  CAS  PubMed  Google Scholar 

  25. Osma MM, Ortuno F, Lozano ML, Gomez-Espuch J, Ayala F, Sanchez-Serrano I et al. Administration of post-autologous PBSCT rhG-CSF is associated with long-term low concentrations of bone marrow hematopoietic progenitor cells. Bone Marrow Transplant 2001; 27: 1287–1292.

    Article  CAS  PubMed  Google Scholar 

  26. Piccirillo N, Sica S, Laurenti L, Chiusolo P, La Barbera EO, Sora F et al. Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1999; 23: 1245–1250.

    Article  CAS  PubMed  Google Scholar 

  27. Shimazaki C, Oku N, Uchiyama H, Yamagata N, Tatsumi T, Hirata T et al. Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1994; 13: 271–275.

    CAS  PubMed  Google Scholar 

  28. Tarella C, Castellino C, Locatelli F, Caracciolo D, Corradini P, Falda M et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998; 21: 401–407.

    Article  CAS  PubMed  Google Scholar 

  29. Valteau-Couanet D, Faucher C, Auperin A, Michon J, Milpied N, Boiron JM et al. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone Marrow Transplant 2005; 36: 547–552.

    Article  CAS  PubMed  Google Scholar 

  30. Vey N, Molnar S, Faucher C, Le Corroller AG, Stoppa AM, Viens P et al. Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: effect on granulocyte recovery. Bone Marrow Transplant 1994; 14: 779–782.

    CAS  PubMed  Google Scholar 

  31. Kubota N, Orita T, Hattori K, Oh-eda M, Ochi N, Yamazaki T . Structural characterization of natural and recombinant human granulocyte colony-stimulating factors. J Biochem 1990; 107: 486–492.

    Article  CAS  PubMed  Google Scholar 

  32. Lieschke GJ, Burgess AW . Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 1992; 327: 28–35.

    Article  CAS  PubMed  Google Scholar 

  33. Lieschke GJ, Burgess AW . Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med 1992; 327: 99–106.

    Article  CAS  PubMed  Google Scholar 

  34. Morstyn G, Burgess AW . Hemopoietic growth factors: a review. Cancer Res 1988; 48: 5624–5637.

    CAS  PubMed  Google Scholar 

  35. Nissen C . Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. Eur J Cancer 1994; 30A (Suppl 3): S12–S14.

    CAS  PubMed  Google Scholar 

  36. Huttmann A, Schirsafi K, Seeber S, Bojko P . Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. J Cancer Res Clin Oncol 2005; 131: 152–156.

    Article  CAS  PubMed  Google Scholar 

  37. Faucher C, Le Corroller AG, Chabannon C, Novakovitch G, Manonni P, Moatti JP et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transplant 1996; 17: 533–536.

    CAS  PubMed  Google Scholar 

  38. Kawano Y, Takaue Y, Mimaya J, Horikoshi Y, Watanabe T, Abe T et al. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT. Blood 1998; 92: 4040–4046.

    CAS  PubMed  Google Scholar 

  39. Trneny M, Slaby J, Valkova V, Apltauerova M, Jelỳnek J, Marinov I et al. Granulocyte-colony stimulating factor administration after autologous peripheral blood progenitor cell transplantion—a prospective randomized trial of 10 μg/kg starting day+1 vs 5 μg/kg starting day +7. Blood 1999; 94 (Suppl 1): 407b (abstract 5046).

    Google Scholar 

  40. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547–2555.

    Article  CAS  PubMed  Google Scholar 

  41. Bolwell B, Goormastic M, Dannley R, Andresen S, Overmoyer B, Mendez Z et al. G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day. Bone Marrow Transplant 1997; 19: 215–219.

    Article  CAS  PubMed  Google Scholar 

  42. Faucher C, Le Corroller AG, Chabannon C, Viens P, Stoppa AM, Bouabdallah R et al. Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery. J Hematother 1996; 5: 663–670.

    Article  CAS  PubMed  Google Scholar 

  43. Olivieri A, Offidani M, Montanari M, Ciniero L, Cantori I, Ombrosi L et al. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica 1998; 83: 329–337.

    CAS  PubMed  Google Scholar 

  44. Huan SD, Yau JC, Dunphy FR, Wallerstein RO, Dicke K, Spencer V et al. Impact of autologous bone marrow infusion on hematopoietic recovery after high-dose cyclophosphamide, etoposide, and cisplatin. J Clin Oncol 1991; 9: 1609–1617.

    Article  CAS  PubMed  Google Scholar 

  45. Metcalf D . Control of granulocytes and macrophages: molecular, cellular, and clinical aspects. Science 1991; 254: 529–533.

    Article  CAS  PubMed  Google Scholar 

  46. de Azevedo AM, Nucci M, Maiolino A, Vigorito AC, Simoes BP, Aranha FJ et al. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 2002; 29: 745–751.

    Article  CAS  PubMed  Google Scholar 

  47. Bence-Bruckler I, Bredeson C, Atkins H, McDiarmid S, Hamelin L, Hopkins H et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 1998; 22: 965–969.

    Article  CAS  PubMed  Google Scholar 

  48. Bolwell BJ, Pohlman B, Andresen S, Kalaycio M, Goormastic M, Wise K et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 1998; 21: 369–373.

    Article  CAS  PubMed  Google Scholar 

  49. Colby C, McAfee SL, Finkelstein DM, Spitzer TR . Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21: 1005–1010.

    Article  CAS  PubMed  Google Scholar 

  50. Cetkovsky P, Koza V, Jindra P, Skopek P, Svojgrova M . Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation. Bone Marrow Transplant 1997; 20: 639–641.

    Article  CAS  PubMed  Google Scholar 

  51. Ballestrero A, Boy D, Gonella R, Miglino M, Clavio M, Barbero V et al. Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Ann Hematol 2008; 87: 49–55.

    Article  PubMed  Google Scholar 

  52. Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant 2005; 35: 1165–1169.

    Article  CAS  PubMed  Google Scholar 

  53. Staber PB, Holub R, Linkesch W, Schmidt H, Neumeister P . Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2005; 35: 889–893.

    Article  CAS  PubMed  Google Scholar 

  54. Vanstraelen G, Frere P, Ngirabacu MC, Willems E, Fillet G, Beguin Y . Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 2006; 34: 382–388.

    Article  CAS  PubMed  Google Scholar 

  55. Berger C, Bertz H, Schmoor C, Behringer D, Potthoff K, Mertelsmann R et al. Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors. Bone Marrow Transplant 1999; 23: 983–990.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Khoury HJ, Loberiza Jr FR, Ringden O, Barrett AJ, Bolwell BJ, Cahn JY et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 2006; 107: 1712–1716.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Przepiorka D, Smith TL, Folloder J, Anderlini P, Chan KW, Korbling M et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001; 97: 3405–3410.

    Article  CAS  PubMed  Google Scholar 

  58. Schriber JR, Chao NJ, Long GD, Negrin RS, Tierney DK, Kusnierz-Glaz C et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994; 84: 1680–1684.

    CAS  PubMed  Google Scholar 

  59. Ho VT, Mirza NQ, Junco Dd D, Okamura T, Przepiorka D . The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant 2003; 32: 771–775.

    Article  CAS  PubMed  Google Scholar 

  60. Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416–423.

    Article  CAS  PubMed  Google Scholar 

  61. Stinson TJ, Adams JR, Bishop MR, Kruse S, Tarantolo S, Bennet CL . Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation. Bone Marrow Transplant 2000; 26: 663–666.

    Article  CAS  PubMed  Google Scholar 

  62. Remberger M, Naseh N, Aschan J, Barkholt L, LeBlanc K, Svennberg P et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant 2003; 32: 217–223.

    Article  CAS  PubMed  Google Scholar 

  63. Hagglund H, Ringden O, Oman S, Remberger M, Carlens S, Mattsson J . A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 1999; 24: 831–836.

    Article  CAS  PubMed  Google Scholar 

  64. Himmelmann B, Himmelmann A, Furrer K, Halter J, Schanz U . Late G-CSF after allogeneic bone marrow or peripheral blood stem cell transplantation: a prospective controlled trial. Bone Marrow Transplant 2002; 30: 491–496.

    Article  CAS  PubMed  Google Scholar 

  65. Ciernik IF, Schanz U, Gmur J . Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Bone Marrow Transplant 1999; 24: 147–151.

    Article  CAS  PubMed  Google Scholar 

  66. Kobayashi S, Imamura M, Hashino S, Noto S, Mori A, Tanaka J et al. Possible role of granulocyte colony-stimulating factor in increased serum soluble interleukin-2 receptor-alpha levels after allogeneic bone marrow transplantation. Leuk Lymphoma 1999; 33: 559–566.

    Article  CAS  PubMed  Google Scholar 

  67. Pan L, Delmonte Jr J, Jalonen CK, Ferrara JL . Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422–4429.

    CAS  PubMed  Google Scholar 

  68. Lee KH, Lee JH, Choi SJ, Kim S, Lee JS, Kim SH et al. Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24: 591–599.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Trivedi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trivedi, M., Martinez, S., Corringham, S. et al. Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transplant 43, 895–908 (2009). https://doi.org/10.1038/bmt.2009.75

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.75

Keywords

This article is cited by

Search

Quick links